FDA Committee Backs ALS Drug as ICER Questions Projected Cost

By a seven to two margin, an FDA advisory committee on Sept. 7 voted that there was enough evidence to support the approval of AMX0035, an oral medication that Amylyx Pharmaceuticals, Inc. is developing for amyotrophic lateral sclerosis (ALS). The vote represented a reversal for the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC), which on March 30 had recommended against the medication’s approval.

Despite the committee’s decision, David Rind, M.D., chief medical officer of the nonprofit Institute for Clinical and Economic Review (ICER), tells AIS Health that Amylyx may have trouble getting the drug covered due to the medication’s likely high cost and lack of clear effectiveness.

© 2022 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

fda-building-and-sign
April 7

After Aduhelm, Congress May Revamp Accelerated Approvals

Read More
covid-pills
February 10

ICER Draft Report Deems Four COVID Drugs Reasonably Priced

READ MORE
holding-an-elderly's-hand
January 13

Medicare Plans to Cover Aduhelm but With Certain Restrictions

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today